Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.
Ghobadi A, Jacobson C, McGuirk J, Shah N, Rossi J, Buchholz T, Bachier-Rodriguez L, Baird J, Diefenbach C, Farooq U, Hernandez-Ilizaliturri F, Isufi I, Patel K, Neelapu S, Sauter C, Spiegel J, Tees M, Timmerman J, Laport G, Frank M. Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy. Journal Of Clinical Oncology 2024, 42: tps7085-tps7085. DOI: 10.1200/jco.2024.42.16_suppl.tps7085.Peer-Reviewed Original ResearchCAR-T cell therapyCD19-directed CAR T-cell therapyDiffuse large B-cell lymphomaT-cell therapyB-cell lymphomaCytokine release syndromeOverall response rateLarge B-cell lymphomaR/R LBCLT cells/kgAdverse eventsAutologous CAR-T cell therapyHigh grade B-cell lymphomaBispecific T-cell engager antibodiesPrimary mediastinal B-cell lymphomaPhase 2 open-labelRecommended phase 2 doseAllogeneic stem cell transplantationGrade B-cell lymphomaMediastinal B-cell lymphomaInduce long-term remissionT-cell engager antibodiesResponse ratePhase 2 doseComplete response rate